Version history

{
  "session_id": "sess_SDA-2026-04-02-gap-ev-ad-biomarkers",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "claude-haiku-4-5",
  "action": "synthesize",
  "content": "# Synthesis: Extracellular Vesicle Biomarkers for Early Alzheimer's Disease Detection\n\nThere is robust consensus that extracellular vesicles (EVs)—particularly exosomes and microvesicles—represent a genuinely promising avenue for early AD detection, grounded in their capacity to cross the blood-brain barrier and carry disease-relevant cargo (phosphorylated tau, amyloid-beta, neurofilament light chain). The scientific community agrees on the biological rationale: EVs directly reflect brain pathology while remaining accessible via minimally invasive blood sampling. However, debate centers on translational readiness. Optimists point to encouraging pilot studies showing EV-derived biomarkers distinguish preclinical AD from controls with reasonable sensitivity/specificity, while pragmatists underscore critical limitations: heterogeneous isolation protocols producing non-reproducible results, inadequate sample sizes, insufficient longitudinal validation, and unclear clinical utility thresholds. This tension reflects a genuine gap between biological plausibility and standardized clinical application.\n\nMoving forward, the field must prioritize *technical standardization and large-scale prospective studies*. Consensus coalesces around three priorities: (1) establishing harmonized EV isolation and characterization methods—possibly through multi-center consortia—to enable meaningful cross-study comparison; (2) conducting well-powered, longitudinal cohort studies tracking EV biomarkers against cognitive decline and neuroimaging endpoints in diverse populations; (3) determining specific clinical decision points where EV biomarkers add independent predictive value beyond established plasma biomarkers (p-tau, phospho-tau181/217, plasma phosphorylated tau ratios). The critical remaining question is not whether EVs *can* reflect AD pathology, but whether their complexity and cost justify clinical adoption compared to emerging ultra-sensitive plasma assays already entering practice.",
  "tokens_used": "463"
}